PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients - Lotan, Tamara L.; Gurel, Bora; Sutcliffe, Siobhan; Esopi, David; Liu, Wennuan; Xu, Jianfeng; Hicks, Jessica L.; Park, Ben H.; Humphreys, Elizabeth; Partin, Alan W.; Han, Misop; Netto, George J.; et al. (Clinical cancer research, 2011)
Keywords: Antineoplastic agents; Biological and medical sciences; Cell Line, Tumor; Cohort Studies; Formaldehyde; Gene Deletion; Gynecology. Andrology. Obstetrics; Humans; Immunohistochemistry - methods; Male; Male genital diseases; Medical sciences; Nephrology. Urinary tract diseases; Paraffin Embedding; Pharmacology. Drug treatments; Prognosis; Prostatic Neoplasms - diagnosis; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - surgery; PTEN Phosphohydrolase - analysis; PTEN Phosphohydrolase - genetics; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Human; Immunohistochemistry; Validation; High risk; Urinary system disease; Prognosis; Prostate disease; Patient; Malignant tumor; Protein; Anatomic pathology; Treatment; Surgery; Cohort study; PTEN Gene; Male genital diseases; Prostate cancer; Public health; Cancer; Tumor suppressor gene